Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
PainTRAINER Program Improves Outcomes for Patients With Systemic Lupus Erythematosus
July 22nd 2021The painTRAINER program included 8 weekly modules, in addition to coping skill activities, in which investigators measured outcomes including the Pain Catastrophizing Scale, pain interference, physical function, anxiety and depression, fatigue, and sleep disturbances.
Read More
Investigators analyzed the effect of biologic therapies in order to determine the effectiveness of this first-line biologic approach in treating systemic juvenile idiopathic arthritis (sJIA) and reducing the exposure of glucocorticoids, a driver of morbidity in this patient population.
Read More
Low Prevalence of Anti-SSA/B in Women With Rheumatoid Arthritis Wishing to Conceive
July 15th 2021Given the low prevalence of anti-Sjögren's-syndrome-related antigen A (anti-SSA) and anti–Sjögren's-syndrome-related antigen B (anti-SSB) in women with rheumatoid arthritis who would like to conceive, intensive echocardiographic screening may not be necessary.
Read More
Erectile Dysfunction Decreases Risk of Cardiovascular Events in Patients With Rheumatoid Arthritis
July 14th 2021Surprisingly, patients with rheumatoid arthritis and erectile dysfunction had a significantly decreased rate of myocardial infarction, heart failure, and death when compared with patients with rheumatoid arthritis alone.
Read More
Tofacitinib and Adalimumab Significantly Improved Pain for Patients With Psoriatic Arthritis
July 13th 2021“This analysis provides information on when clinically meaningful improvements in pain may be expected in patients with psoriatic arthritis receiving tofacitinib or adalimumab, and how baseline pain severity may impact response to tofacitinib, which is of value in clinical practice,” stated investigators.
Read More
Overdrive Podcast: Value-Based Care in Rheumatology
July 13th 2021On the latest episode of Overdrive, we sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Read More
Richard Furie, MD: Safety and Efficacy of BIIB059 for Systemic Lupus Erythematosus
July 9th 2021Richard Furie, MD, explains the safety and efficacy of BIIB059 for patients with systemic lupus erythematosus (SLE), the study design and background on his upcoming SLE study, and Biogen’s ongoing commitment to including underrepresented groups in its clinical trials.
Read More
Christopher Ritchlin, MD, MPH: Safety and Efficacy of Bimekizumab for Psoriatic Arthritis
July 5th 2021Christopher Ritchlin, MD, MPH, discusses the safety and efficacy of bimekizumab in patients with psoriatic arthritis, the BE ACTIVE study, the clinical significance of these results, and his plans for future research on this topic.
Read More
Andrew L Concoff, MD, FACR, CAQSM: Value-Based Care
June 29th 2021Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Read More
Serum Protein Biomarker Panel Differentiates Between Psoriatic Arthritis and Rheumatoid Arthritis
June 24th 2021In patients with early inflammatory arthritis, a serum protein biomarker panel was proven effective in separating patients with psoriatic arthritis from those with rheumatoid arthritis.
Read More
Guidelines for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic
June 23rd 2021The American College of Rheumatology has updated its treatment guidelines for the management of pediatric rheumatic disease during the COVID-19 pandemic. The guideline includes 33 final guidance recommendations, 8 of which received moderate-to-high task force consensus.
Read More
Upadacitinib Effectively Treats Patients With Psoriatic Arthritis and Axial Involvement
June 22nd 2021Upadacitinib (UPA) effectively treated patients with psoriatic arthritis (PsA) and axial involvement, a group that is historically more likely to have higher disease burden and more quality-of-life impairments than patients without axial involvement.
Read More
Safety and Efficacy of Secukinumab for Juvenile Idiopathic Arthritis
June 21st 2021Rheumatology Network interviewed Hermine Brunner, MD, MSc, MBA, lead investigator of the JUNIPERA study, which reported on the safety and efficacy of secukinumab for patients with juvenile idiopathic arthritis (JIA), presented at the EULAR 2021 Virtual Congress. Secukinumab was the first approved biologic for specific JIA categories in the US and marked improvement of skin involvement with juvenile spondyloarthritis (jPSA) and increased quality of life for children with chronic arthritis plus psoriasis.
Read More
Alexis Ogdie, MD: Importance of Patient Experience in Psoriatic Arthritis Treatment
June 14th 2021In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.
Read More